News & Views
SSB signs distribution deal for endonuclease
May 22 2012
Sartorius Stedim Biotech (SSB) has signed a worldwide sales and distribution agreement for c-LEcta’s proprietary Serratia marcescens nuclease for biopharmaceutical applications. The customised endonuclease is available under the product name Denarase through all regular SSB sales channels.
c-LEcta has optimised the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins.
“This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance,”said Dr. Uwe Gottschalk, VicePresident of Purification Technologies at Sartorius Stedim Biotech.
“The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total
solution provider for the biopharmaceutical industry.”
Dr. Marc Struhalla, Managing Director of c-LEcta added: “The technology developed by
c-LEcta allows us to provide nuclease to our customers in the highest quality. We are convinced that with Sartorius Stedim Biotech, we have found the right sales and distribution partner for the successful worldwide commercialisation of our product.”
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
May 05 2024 Seville, Spain
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA
May 15 2024 Birmingham, UK
May 21 2024 Lagos, Nigeria